Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia

Blood

Volumn 119, Issue 12, 2012, Pages 2854-2862

  Rossi, Davide ^a   Fangazio, Marco ^a   Rasi, Silvia ^a   Vaisitti, Tiziana ^b   Monti, Sara ^a   Cresta, Stefania ^a   Chiaretti, Sabina ^c   Del Giudice, Ilaria ^c   Fabbri, Giulia ^d   Bruscaggin, Alessio ^a   Spina, Valeria ^a   Deambrogi, Clara ^a   Marinelli, Marilisa ^c   Famà, Rosella ^a   Greco, Mariangela ^a   Daniele, Giulia ^e   Forconi, Francesco ^f,g   Gattei, Valter ^h   Bertoni, Francesco ^i,j   Deaglio, Silvia ^b   Pasqualucci, Laura ^d,k,l   Guarini, Anna ^c   Dalla Favera, Riccardo ^d,l   Foà, Robin ^c   Gaidano, Gianluca ^a   more..

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g UNIVERSITY OF SIENA   (Italy)

^h CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

ⁱ INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^j ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^k UNIVERSITY OF PERUGIA   (Italy)

^l NewYork Presbyterian Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RITUXIMAB;

ADULT; AGED; ARTICLE; BIRC 3 GENE; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; GENE; GENE DISRUPTION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

EID: 84858859064     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-395673     Document Type: Article

References (50)

1. Müller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. Swerdlow S, Campo E, Harris NL, eds; International Agency for Research on Cancer. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Geneva, Switzerland: World Health Organization; 2008:180-182.
2. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood. 2008; 111(12):5446-5456.
3. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8): 804-815.
4. Rossi D, Gaidano G. Richter syndrome: molecular insights and clinical perspectives. Hematol Oncol. 2009;27(1):1-10.
5. Rossi D, Spina V, Cerri M, et al. Stereotyped Bcell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res. 2009;15(13): 4415-4422.
6. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391-3401.
7. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol. 2011;8(1):38-47.
8. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-488.
9. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26): 1910-1916. (Pubitemid 32064784)
10. Zenz T, Kröber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322-3329.
11. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15(3):995-1004.
12. Stilgenbauer S, Liebisch P, James MR, et al. Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3- 923.1 in lymphoproliferative disorders. Proc Natl Acad Sci U S A. 1996;93(21):11837-41. (Pubitemid 26347210)
13. Schaffner C, Stilgenbauer S, Rappold GA, Döhner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood. 1999;94(2):748- 753.
14. Austen B, Powell JE, Alvi A, et al. Mutations in the ATM gene lead to impaired overall and treatmentfree survival that is independent of IGVH mutation status in patients with B-CLL. Blood. 2005; 106(9):3175-3182. (Pubitemid 41565916)
15. Guarini A, Marinelli M, Tavolaro S, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica. 2012;97(1):47-55.
16. Skowronska A, Austen B, Powell JE, et al. ATM germline heterozygosity does not play a role in CLL initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica. 2012;97(1):142-146.
17. Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114(13):2589- 2597.
18. Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473-4479.
19. Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol. 2011;29(16):2223-2229.
20. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
21. Puente XS, Pinyol M, Quesada V, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
22. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011;118(26): 6904-6908.
23. Rossi D, Rasi S, Fabbri G, et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012; 119(2):521-529.
24. Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autocrine pathway. Blood. 2004;103(2):679-688. (Pubitemid 38145555)
25. Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia Bcell survival through activation of the canonical NF-kappaB pathway. Blood. 2007;109(2):703- 710.
26. Hewamana S, Alghazal S, Lin TT, et al. The NFkappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008;111(9): 4681-4689.
27. Buggins AG, Pepper C, Patten PE, et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res. 2010;70(19):7523-7533.
28. Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
29. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NFkappaB in diffuse large B-cell lymphoma. Nature. 2009;459(7247):717-721.
30. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2(6): a000109.
31. Vallabhapurapu S, Karin M. Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol. 2009;27:693- 733.
32. Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 2002;416(6878):345-347.
33. Zarnegar BJ, Wang Y, Mahoney DJ, et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol. 2008;9(12):1371- 1378.
34. Conze DB, Zhao Y, Ashwell JD. Non-canonical NF-κB activation and abnormal B cell accumulation in mice expressing ubiquitin protein ligaseinactive c-IAP2. PLoS Biol. 2010;8(10): e1000518.
35. Rossi D, Deaglio S, Dominguez-Sola D, et al. Alteration of BIRC3 and multiple other NF-{kappa}B pathway genes in splenic marginal zone lymphoma. Blood. 2011;118(18):4930-4934.
36. Rasi S, Bruscaggin A, Rinaldi A, et al. Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. Leuk Res. 2011;35(10):1419-1422.
37. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848- 1854.
38. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840-1847. (Pubitemid 29430399)
39. Rinaldi A, Mian M, Kwee I, et al. Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. Br J Haematol. 2011;154(5):590-599.
40. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc. 1958;53:457-481.
41. Cox DR. Regression models and life tables. J R Stat Assoc. 1972;34:187-220.
42. Harrell FE Jr. Regression Modeling Strategies. New York, NY: Springer-Verlag; 2001:465-522.
43. Schoenfeld D. Partial residuals for the proportional hazard regression model. Biometrika. 1982;69(1):239-241.
44. Chen CH, George SL. The bootstrap and identification of prognostic factors via Cox's proportional hazards regression model. Stat Med. 1955;4(1): 39-46.
45. Rasi S, Monti S, Spina V, Foa' R, Gaidano G, Rossi D. Analysis of NOTCH1 mutations in monoclonal B cell lymphocytosis. Haematologica. 2012;97(1):153-154.
46. Hewamana S, Lin TT, Jenkins C, et al. The novel nuclear factor-kappaB inhibitor LC-1 is equipotent in poor prognostic subsets of chronic lymphocytic leukemia and shows strong synergy with fludarabine. Clin Cancer Res. 2008;14(24):8102-8111.
47. Hertlein E, Wagner AJ, Jones J, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood. 2010;116(1):45-53.
48. Hertlein E, Byrd JC. Signalling to drug resistance in CLL. Best Pract Res Clin Haematol. 2010; 23(1):121-131.
49. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117(23):6287- 6296.
50. Kalla C, Scheuermann MO, Kube I, et al. Analysis of 11q22-q23 deletion target genes in B-cell chronic lymphocytic leukaemia: evidence for a pathogenic role of NPAT, CUL5, and PPP2R1B. Eur J Cancer. 2007;43(8):1328-1335. (Pubitemid 46720247)